Mechanisms of resistance of HIV-1 primary isolates to complement- mediated lysis

Virology

Volumn 246, Issue 2, 1998, Pages 370-378

  Takefman, Daniel M ^a   Sullivan, Brenda L ^a   Sha, Beverly E ^b   Spear, Gregory T ^a  

^a RUSH UNIVERSITY   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032486586     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9205     Document Type: Article

References (43)

1. Arthur L. O., Bess J. W. Jr., Sowder R. C. D., Benveniste R. E., Mann D. L., Chermann J. C., Henderson L. E. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 258:1992;1935-1938.
2. Back N. K., Smit L., De Jong J. J., Keulen W., Schutten M., Goudsmit J., Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology. 199:1994;431-438.
3. Banapour B., Sernatinger J., Levy J. A. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology. 152:1986;268-271.
4. Benjouad A., Gluckman J. C., Rochat H., Montagnier L., Bahraoui E. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J. Virol. 66:1992;2473-2483.
5. Bolmstedt A., Olofsson S., Sjogren-Jansson E., Jeansson S., Sjoblom I., Akerblom L., Hansen J. E., Hu S. L. Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J. Gen. Virol. 73:1992;3099-3105.
6. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:1994;6006-6013.
7. Burton D. R., Pyati J., Koduri R., Sharp S. J., Thornton G. B., Parren P. W., Sawyer L. S., Hendry R. M., Dunlop N., Nara P. L. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
8. D'Souza M. P., Livnat D., Bradac J. A., Bridges S. H. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J. Infect. Dis. 175:1997;1056-1062.
9. Davis D., Stephens D. M., Willers C., Lachmann P. J. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J. Gen. Virol. 71:1990;2889-2898.
10. Fouts T. R., Binley J. M., Trkola A., Robinson J. E., Moore J. P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:1997;2779-2785.
11. Hollinger F. B., Bremer J. W., Myers L. E., Gold J. W., McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J. Clin. Microbiol. 30:1992;1787-1794.
12. Innocenti-Francillard P., Brengel K., Guillon C., Mallet F., Morand P., Gruters R., Seigneurin J. M. Blood monocytes infected in vivo by HIV-1 variants with a syncytium-inducing phenotype. AIDS Res. Hum. Retroviruses. 10:1994;683-690.
13. Karlsson G. B., Gao F., Robinson J., Hahn B., Sodroski J. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J. Virol. 70:1996;6136-6142.
14. Kusumi K., Conway B., Cunningham S., Berson A., Evans C., Iversen A. K., Colvin D., Gallo M. V., Coutre S., Shpaer E. G. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J. Virol. 66:1992;875-885.
15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London). 227:1970;680-685.
16. Marschang P., Sodroski J., Wurzner R., Dierich M. P. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25:1995;285-290.
17. Meyerhans A., Cheynier R., Albert J., Seth M., Kwok S., Sninsky J., Morfeldt-Manson L., Asjo B., Wain-Hobson S. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell. 58:1989;901-910.
18. Montefiori D. C., Cornell R. J., Zhou J. Y., Zhou J. T., Hirsch V. M., Johnson P. R. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology. 205:1994;82-92.
19. Moog C., Fleury H., Pellegrin I., Kirn A., Aubertin A. M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:1997;3734-3741.
20. Moore J. P., Burkly L. C., Connor R. I., Cao Y., Tizard R., Ho D. D., Fisher R. A. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses. 9:1993;529-539.
21. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. r., Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:1995;101-109.
22. Moore J. P., Wallace L. A., Follett E. A., McKeating J. A. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS. 3:1989;155-163.
23. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:1993;6642-6647.
24. O'Brien W. A., Mao S. H., Cao Y., Moore J. P. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J. Virol. 68:1994;5264-5269.
25. Piatak M. Jr., Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 259:1993;1749-1754.
26. Poignard P., Klasse P. J., Sattentau Q. J. Antibody neutralization of HIV-1. Immunol. Today. 17:1996;239-246.
27. Saarloos M. N., Sullivan B. L., Czerniewski M. A., Parameswar K. D., Spear G. T. Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J. Virol. 71:1997;1640-1643.
28. Sabino E., Pan L. Z., Cheng-Mayer C., Mayer A. Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasi-species to short-term tissue culture isolates: An analysis of tat and C2-V3 env regions. AIDS. 8:1994;901-909.
29. Saifuddin M., Ghassemi M., Patki C., Parker C. J., Spear G. T. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res. Hum. Retroviruses. 10:1994;829-837.
30. Saifuddin M., Hedayati T., Atkinson J. P., Holguin M. H., Parker C. J., Spear G. T. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78:1997;1907-1911.
31. Saifuddin M., Parker C. J., Peeples M. E., Gorny M. K., Zolla-Pazner S., Ghassemi M., Rooney I. A., Atkinson J. P., Spear G. T. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182:1995;501-509.
32. Sawyer L. S., Wrin M. T., Crawford-Miksza L., Potts B., Wu Y., Weber P. A., Alfonso R. D., Hanson C. V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68:1994;1342-1349.
33. Spear G. T., Sullivan B. L., Landay A. L., Lint T. F. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J. Virol. 64:1990;5869-5873.
34. Spear G. T., Takefman D. M., Sharpe S., Ghassemi M., Zolla-Pazner S. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology. 204:1994;609-615.
35. Spear G. T., Takefman D. M., Sullivan B. L., Landay A. L., Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 67:1993;53-59.
36. Spira A. I., Ho D. D. Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J. Virol. 69:1995;422-429.
37. Sullivan B. L., Knopoff E. J., Saifuddin M., Takefman D. M., Saarloos M. N., Sha B. E., Spear G. T. Susceptibility of HIV-1 plasma virus to complement-mediated lysis: Evidence for a role in clearance of virus in vivo. J. Immunol. 157:1996;1791-1798.
38. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:1995;4413-4422.
39. Tremblay M., Wainberg M. A. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162:1990;735-737.
40. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J. P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1996;1100-1108.
41. Tsang M. L., Evans L. A., McQueen P., Hurren L., Byrne C., Penny R., Tindall B., Cooper D. A. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J. Infect. Dis. 170:1994;1141-1147.
42. Wrin T., Crawford L., Sawyer L., Weber P., Sheppard H. W., Hanson C. V. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 7:1994;211-219.
43. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA. 79:1982;2031-2035.